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High loads of human papillomavirus (HPV) 16 and HPV 18/45 increase the risk of developing invasive cervical carcinoma, revealing
higher risk in percentiles of highest viral loads for HPV 16 (odds ratio (OR) 58.7, 95% confidence interval (CI) 21.9–151.4) compared
to HPV 18/45 (OR 3.3, 95% CI 1.5–7.2). Thus, HPV load is a type-dependent risk marker for invasive carcinoma.
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Human papillomavirus (HPV) is a necessary cause of cervical
cancer, but the high prevalence of transient infections makes
detection of the presence or absence of virus an inefficient means
of identifying women at risk of developing cervical cancer (Ho et al,
1998; Jacobs et al, 2000). Viral load has been suggested as a marker
of nontransient infection, and high HPV load in smears with
normal cytology has been associated with the risk of developing
dysplasia and carcinoma in situ (CIS) (Josefsson et al, 2000; van
Duin et al, 2002; Dalstein et al, 2003; Moberg et al, 2004). However,
it is not known whether high viral load is also predictive of
invasive cervical cancer, as past studies have pooled the outcomes
of invasive cancers together with earlier stages of the disease
(Lorincz et al, 2002; Sherman et al, 2002, 2003; Sun et al, 2002;
Dalstein et al, 2003; Gravitt et al, 2003). Integration of high-risk
HPV into the cell genome has been suggested to play a pivotal role
in malignant transformation (Boshart et al, 1984; Cullen et al,
1991; Daniel et al, 1997). As a consequence, the association
between viral load and development of CIS may not automatically
imply a strong association of high viral load and progression into
invasive carcinoma. Here, we determine whether viral load in
cervical smears is a risk marker of later developing invasive
cervical cancer.
MATERIALS AND METHODS
Cases diagnosed with invasive squamous-cell carcinoma of the
cervix and with registered smears taken at least 1 year prior to the
diagnosis date were identified from the organised screening
program (PAP-smear register) and the tumour register at the
Clinic of Pathology, Uppsala Academic Hospital and Uppsala
University, Sweden. Controls were selected from the same
organised screening programme and have been described in detail
elsewhere (Ylitalo et al, 2000). Birth years of cases and controls
ranged from 1922 to 1968. Two strategies were used to select
smears from both cases and controls. The screening history of
individual women was examined to identify suitable smears for
inclusion. First, we attempted to study an early phase of the
infection. Therefore, we started from the date of diagnosis and
stepped backwards in the screening history until reaching a smear
fulfilling the criteria of (a) being negative itself, (b) being preceded
by a normal smear or being preceded by an abnormal smear taken
at least 3 years earlier, or being the first registered smear. The time
span of 3 years was chosen to increase the likelihood of
spontaneous regression of the preceding lesion (Schlecht et al,
2003), and consequently decreasing the risk of selecting false-
negative smears. Secondly, up to three smears per woman were
chosen from cases and controls at random to increase the chance
of including an existing HPV infection. Smears collected less than
1 year prior to diagnosis were excluded. DNA was extracted from
archival PAP smears using previously described methods (Josefs-
son et al, 1999), and amounts of human genomic DNA, HPV 16,
HPV 31 and a combined load for HPV 18 and 45 were estimated
using published methods (Moberg et al, 2003). Viral load is
reported as HPV genomes per cell equivalent. An estimate of 6.6pg
per human cell was used to convert human DNA estimates into cell
equivalents (CE). The strategy of a combined load of HPV 18 and
45 was employed to minimise the number of parallel quantitative
PCR reactions. Odds ratios (ORs) were estimated by logistic
regression (LOGISTIC procedure, SAS v6.12, SAS Institute Inc.,
Cary NC, USA).
RESULTS
A single, normal smear was obtained from 62 cases and
501 controls (Table 1). The smears were collected on average 9
years (range 1–28) prior to the diagnosis date and classified
as negative for squamous cell abnormalities. A total of 10 cases
had registered abnormal cytology during the screening
interval before the collection of the normal smear included in this
study. Four cases had diagnoses equivalent to ASCUS or LSIL, and
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ssix cases HSIL, as the worst registered lesion prior to the
normal smear. However, in these four cases, the smear taken
closest before the selected smear was classified as negative for
lesions.
In all, 45% of cases and 6% of controls test positive for HPV 16
(Table 1). In estimating the risk, crude ORs are presented since
initial introduction of birth year and age at smear collection in the
regression model did not alter the estimates appreciably. Odds
ratio increases with HPV 16 viral load, reaching a maximum of
OR¼51 in the percentile with the highest viral load (Table 2). HPV
31 is found in 8% of cases and 4% of controls and HPV 18/45,
detected together, are found in 13% of cases and 6% of controls.
The ORs for HPV 31 and HPV 18/45 are significant for the
percentiles with the highest viral load (Table 2).
The random set includes 139 cases (261 smears) and 548
controls (1049 smears) (Table 1). In all, 168 (64%) of the included
smears from cases were classified as negative for malignant
cells. The corresponding number for controls is 819 (78%).
Cytological information was missing in the archives for a total of
five smears from cases and 188 smears from controls. In total, 63%
of cases and 10% of controls test positive for HPV 16 (Table 2).
The OR, calculated from the mean HPV 16 viral load per
woman, increased with viral load and reached a maximum
of OR¼59 for the percentile with the highest viral load (Table 2).
The ORs for HPV 31 are not significant, while the OR for HPV 18/
45 is significant for the percentile with the highest viral load
(Table 2).
DISCUSSION
Our results indicate that increasing viral load of HPV 16 in cervical
smears increases the risk of future invasive cervical cancer. For
HPV 18/45, a significant OR was only seen for the highest viral-load
percentile. The relationship between OR of invasive cancer and
viral load of HPV 16 is similar to that previously described for CIS
(Moberg et al, 2004) (Figure 1); consistent with this, CIS and
invasive cervical cancer reflect the same basic aetiology. Thus, our
results show that a high viral load in PAP smears is a risk factor not
only for the development of CIS but also for invasive cancer. Our
data support the hypothesis of Peitsaro et al (2002) that high viral
loads are likely to increase the risk for events initiating dysplasia
such as viral integration. Given that integration is a random event,
the risk for such an event would increase with high viral loads,
independent of whether a high viral load reflects widespread
infection or high copy numbers per cell. HPV 16 displays a
generally higher risk for invasive cervical cancer development over
viral load categories than HPV 18 and HPV 31. Interestingly, HPV
16 appears to be able to induce malignant transformation without
integration (Pirami et al, 1997; Badaracco et al, 2002; Hudelist et al,
2004). This indicates that additional factors to integration may be
important for malignant transformation. Longitudinal studies
including both the physical state and load of the virus are
needed in order to determine their relative importance for
development of cervical cancer. Judging from our data, HPV load
provides information about the risk for subsequent development of
Table 1 Characteristics of the case-control material
Single smear cohort Random smear cohort
Cases Controls Cases Controls
n 62 501 139 548
Year of birth
Mean 1946.8 1949.0 1946.6 1949.0
Range 1922–1965 1922–1968 1922–1968 1922–1968
Age at smear collection
Mean 34.7 30.9 34.6 29.8
Range 20–62 15–63 15–62 15–63
Human DNA
Mean
a 159.8 219.2 175.7 206.2
Range 5.0–1354 5.4–6264 5.0–2465 5.0–15914
HPV 16
No of positive women 28 28 87 56
No of positive smears 28 28 120 66
Mean viral load
b 138.3 17.7 97.0 12.9
Range 0.05–2812 0.02–300.3 0.03–2812 0.01–300.3
HPV 31
No of positive women 5 19 9 34
No of positive smears 5 19 15 39
Mean viral load
b 17.7 37.4 29.8 50.5
Range 0.50–36.7 0.03–543.1 0.3–147.2 0.02–762.6
HPV 18/45
No of positive women 8 28 28 55
No of positive smears 8 28 39 64
Mean viral load
b 157.6 77.2 265.3 71.4
Range 0.11–1158 0.01–1402 0.02–5105 0.01–2044
aMean estimated number of human cells equivalents per reaction.
bMean number of HPV genomes per human cell equivalent.
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sinvasive carcinomas, but the extent correlates strongly with the
HPV type.
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Figure 1 Odds ratio with 95% CI of cervical CIS (empty bars) or invasive
cervical carcinoma (filled bars) depending on HPV 16 load. VL* represents
the number of HPV 16 genomes per human cell equivalent.
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